With one in two of us receiving a cancer diagnosis at some point during our lives, it has never been more important to improve the outcomes for people affected by cancer.
This cancer research podcast is brought to you by The University of Manchester in partnership with the Manchester Cancer Research Centre (MCRC). In each episode, our cancer researchers discuss the innovations, discoveries and projects that are changing the landscape of early detection.
All content for One in Two is the property of The University of Manchester and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
With one in two of us receiving a cancer diagnosis at some point during our lives, it has never been more important to improve the outcomes for people affected by cancer.
This cancer research podcast is brought to you by The University of Manchester in partnership with the Manchester Cancer Research Centre (MCRC). In each episode, our cancer researchers discuss the innovations, discoveries and projects that are changing the landscape of early detection.
One in Two podcast - The basic biology of lung cancer with Dr Colin Lindsay: Exploring oncogenic drivers such as the KRAS mutation
One in Two
1 hour 11 minutes
2 years ago
One in Two podcast - The basic biology of lung cancer with Dr Colin Lindsay: Exploring oncogenic drivers such as the KRAS mutation
In this episode, we speak to Dr Colin Lindsay, Clinical Senior Lecturer at The Christie and The University of Manchester about the basic biology of lung cancer, focusing on: The high incidence of lung cancer here in Manchester The differences between non-small cell and small-cell lung cancer Oncogenic drivers in lung cancer such as the KRAS mutation His work on the drug sotorasib which targets KRAS mutant cancer and has now been approved by the FDA and for use in the UK by NICE Colin Lindsay's research profile EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells KRAS: Reasons for optimism in lung cancer On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial Molecular characterization of primary and secondary resistance to RET inhibitors in patients with advanced NSCLC and RET fusions (2022) https://www.ejcancer.com/article/S0959-8049(22)00871-1/fulltext
One in Two
With one in two of us receiving a cancer diagnosis at some point during our lives, it has never been more important to improve the outcomes for people affected by cancer.
This cancer research podcast is brought to you by The University of Manchester in partnership with the Manchester Cancer Research Centre (MCRC). In each episode, our cancer researchers discuss the innovations, discoveries and projects that are changing the landscape of early detection.
